Pfizer receives patient information, including mobile phone numbers and email addresses, as part of the scheme, under which it provides regular information to patients about their condition and medication.
Like the Blackmores deal, when one of nine Pfizer drugs is being dispensed, the guild's computer system prompts pharmacists that patients are eligible for a support program.
One of the drugs included in the scheme is Pfizer's cholesterol-lowering blockbuster Lipitor, for which more than 10 million prescriptions were filled last year through the Pharmaceutical Benefits Scheme at a cost to the taxpayer of almost $600 million.
Pfizer will face competition from cheaper generic versions of the drug when its patent expires early next year.
Patients who sign up for the 12-week support program linked to Lipitor receive a cookbook and weekly emails containing health advice. Other Pfizer drugs with associated support programs are Champix, Xalatan, Viagra, Lyrica, Pristiq, Aricept, Celebrex and Effexor XR.
A pharmacist who did not wish to be named said: ''Pharmacists might get a short-term gain of $7 but they are putting patient information into the hands of a drug manufacturer who is obviously going to promote their products directly to that patient.
''It's a back-door way of promoting and advertising.''